Slide 1: Q4 2022 Earnings Call
„ Q4 2022 Earnings Call March 6, 2023
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a
Slide 3: Corporate Transformation: Progress on Assay Redevelopment Roadmap
Corporate Transformation: Progress on Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 H1 2023 H2 2023 CEO transition on Strategic review Stability and variance Manufacturing Process automation April 25th completed in July, improvements for implementation Process scaling business real
Slide 4: Q4 2022 Results
Q4 2022 Results (in millions) GAAP Operating Expenses Q4 GAAP Q4 Non-GAAP 36.2 SG&A and 24.9 2021 2022 2021 2022 R&D * 30.3 30.3 Restructuring 0.0 Revenue (29.3 excl. 25.8 (29.3 excl. 25.8 and RADx) RADx) Impairment 9.7 Gross Margin $ 16.3 12.6 14.3 10.7 *Reflects the impact of the August restructur
Slide 5: Q4 2022 Cash & Cash Burn
Q4 2022 Cash & Cash Burn (in millions) 346.3 $m Cash Balance -5.0 & Cash Usage 2.1 1.6 341.3 18.6 13.0 EO Q3 2022 Net Loss Non Working CAPEX EO Q4 FY22 Cash Activities Capital and Others Note: Ending total cash $341.3M; unrestricted cash balance $338.7 and restricted cash balance $2.6M 5
Slide 6: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others 2022 Advances PUBLICATIONS BIOMARKERS INSTRUMENTS Cumulative Cumulative Placements 538 # of units placed Cumulative 876 2,141 46 480 130 98 41 46 3 225 708 403 44 73 193 1,575 330 113 322 177 535 168 28
Slide 7: 2023 Guidance
2023 Guidance Expect modest growth in 2023, as we continue to make progress on our corporate Transformation; return to double digit growth by 2024 Revenue (in millions) $105.5 $103 - $109 $5.0 Lilly MCA License fee $3.0 ~$6.0 Lilly MCA Project Gross Margin • Expect to end 2023 with GAAP gross margin
Slide 8: Simoa p-Tau 181 test; biomarker endpoint on Leqembi label
Simoa p-Tau 181 test; biomarker endpoint on Leqembi label 10 mg/kg Leqembi every two weeks reduced mean plasma pTau-181 24% from baseline in 79 weeks, a highly significant decrease. 10 mg/kg every two weeks Amyloid Beta PET Composite SUVR N=44 N=98 Mean baseline 1.373 1.402 Adjusted mean change from
Slide 9: Simoa biomarkers to assess disease progression in MS
Simoa biomarkers to assess disease progression in MS Simoa biomarkers have proven invaluable in MS research and drug development efforts Early work used Simoa NfL to show help show that EBV was a causative agent of MS in patients This study suggests that sGFAP is a prognostic biomarker for fut
Slide 10: Prospective clinical study: Simoa Biomarkers detect AD up to 17 years before Dx
Prospective clinical study: Simoa Biomarkers detect AD up to 17 years before Dx Results from prospective cohort followed over 17 years Simoa GFAP was associated with clinical AD incidence 9 to 17 years before diagnosis Simoa pTau181 and NfL were associated with AD incidence within 9 years of d
Slide 11: Leader in proteomics, positioning ourselves to accelerate faster
Most Sensitive Protein Measurements in Blood Strong IP protection Translational Leader FDA - BTD pTau181, NfL LDT implementation Pharma / KOL partnerships Sample to Answer Platform Leader in proteomics, Rapid TAT; global footprint positioning ourselves to Continued Innovation accelerate faster Simoa
Slide 12: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Three Months Ended December Three Months Ended September Year Ended December 31, 31, Ended June 30, 30, 2022 2021 2022 2022 2022 2021 GAAP gros
Slide 13: Supplemental Schedule of Operating Expenses
Quanterix Corporation Supplemental Schedule of Operating Expenses (Unaudited and in thousands) Three Months Ended December 31 2022 2021 Operating expenses: Research and development $ 5,600 $ 7,734 Selling, general and administrative 19,272 28,423 Subtotal $ 24,872 $ 36,157 Other lease costs 669 — Re